Cymbalta Gets FDA Approval For Anxiety Maintenance Treatment

Eli Lilly today announced that the FDA has approved its anti-depressant Cymbalta as a maintenance treatment for generalized anxiety disorder. That marks the sixth indication for the multi-billion selling drug, which is also approved for use in depression, anxiety, fibromyalgia and diabetic neuropathic pain.

Go to Source

Related posts:

  1. Cymbalta Sales Way Up
  2. Lilly Sponsors Fibromyalgia Website
  3. Zyprexa Gets FDA Approval For Use In Adolescents
  4. Report: Cymbalta Linked To Serotonin Syndrome In Australian Patients
  5. Seroquel Gets FDA Approval For Use In 10-Year-Olds

Leave a Reply

 
Special Offers
Blogroll

Pages
Tags